Drug Trial Radar · NCT01677572
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
197
Actual
Start
Oct 5, 2012
Primary completion
Jul 31, 2019
Study completion Jul 31, 2019
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Sep 3, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of multiple doses of Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) in participants with prodromal or mild Alzheimer's Disease (AD). The secondary objectives of this study are to assess the effect on cerebral amyloid plaque content as measured by florbetapir-fluorine-18 (18F-AV-45F-AV-45) positron emission tomography (PET) imaging, to assess the multiple dose serum concentrations of Aducanumab and to evaluate the immunogenicity of Aducanumab after multiple dose administration in this population.
Conditions
- Alzheimer's Disease
Interventions
Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)Drug
Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
PlaceboDrug
Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: Baseline to week 518
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
NNS Clinical Research, LLC
Tucson, Arizona
Senior Clinical Trials, Inc.
Laguna Hills, California
Torrance Clinical Research Institute, Inc.
Lomita, California
Collaborative Neuroscience Network, LLC
Long Beach, California
University of California, Los Angeles
Los Angeles, California
Pacific Neuroscience Medical Group
Oxnard, California
Pacific Research Network, Inc.
San Diego, California
San Francisco Clinical Research Center
San Francisco, California
Stanford University Medical Center
Stanford, California
Alzheimer's Disease Research Unit, Yale University
New Haven, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
Brain Matters Research, Inc.
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
MD Clinical Trials, Inc.
Hallandale, Florida
Miami Jewish Health Systems
Miami, Florida
Galiz Research, LLC
Miami Springs, Florida
Compass Research, LLC
Orlando, Florida
Infinity Clinical Research, Inc.
Sunrise, Florida
Axiom Clinical Research of Florida
Tampa, Florida
Stedman Clinical Trials, LLC
Tampa, Florida
Neurostudies.net, LLC
Decatur, Georgia
Alexian Brothers Neurosciences Institute
Elk Grove Village, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
St. Louis Clinical Trials, LLC
St Louis, Missouri
Memory Enhancement Center of America, Inc.
Eatontown, New Jersey
CRI Lifetree
Marlton, New Jersey
Advanced Memory Research Institute of NJ
Toms River, New Jersey
Empire Neurology, PC
Latham, New York
Insight Clinical Trials LLC
Beachwood, Ohio
Summit Research Network (Oregon) Inc.
Portland, Oregon
Brown Hospital
East Providence, Rhode Island
Rhode Island Hospital
Providence, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.